Open AccessA prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting
Author(s) -
Marilyn L. Kwan,
Joan C. Lo,
Cecile A. Laurent,
Janise M. Roh,
Li Tang,
Christine B. Ambrosone,
Lawrence H. Kushi,
Charles P. Quesenberry,
Song Yao
Publication year - 2021
Publication title -
journal of cancer survivorship
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.524
H-Index - 63
eISSN - 1932-2267
pISSN - 1932-2259
DOI - 10.1007/s11764-021-00993-0
Subject(s) - medicine , osteoporosis , breast cancer , hazard ratio , prospective cohort study , hip fracture , body mass index , physical therapy , women's health initiative , proportional hazards model , cancer , confidence interval , observational study
Fracture and osteoporosis are known side effects of aromatase inhibitors (AIs) for postmenopausal hormone receptor positive (HR+) breast cancer (BC) patients. How modifiable lifestyle factors impact fracture risk in these patients is relatively unknown.